Smith Salley Wealth Management Acquires 1,469 Shares of Johnson & Johnson $JNJ

Key Points

• Smith Salley Wealth Management increased its stake in Johnson & Johnson by 3.3%, acquiring an additional 1,469 shares during the second quarter, bringing its total holdings to 45,947 shares valued at approximately $7 million.
• Johnson & Johnson reported earnings of $2.77 per share for the last quarter, exceeding estimates, with a revenue of $23.74 billion, a 5.8% increase year-over-year.
• The company announced a quarterly dividend of $1.30 per share, representing an annualized dividend yield of 2.9%, with an ex-dividend date on August 26th.

Smith Salley Wealth Management raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,947 shares of the company's stock after purchasing an additional 1,469 shares during the period. Smith Salley Wealth Management's holdings in Johnson & Johnson were worth $7,018,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Symmetry Partners LLC raised its stake in Johnson & Johnson by 13.1% during the second quarter. Symmetry Partners LLC now owns 6,476 shares of the company's stock valued at $989,000 after buying an additional 748 shares during the last quarter. Wagner Wealth Management LLC raised its position in shares of Johnson & Johnson by 13.1% in the 2nd quarter. Wagner Wealth Management LLC now owns 4,186 shares of the company's stock worth $639,000 after purchasing an additional 486 shares during the last quarter. Sonora Investment Management Group LLC grew its position in Johnson & Johnson by 0.5% during the 2nd quarter. Sonora Investment Management Group LLC now owns 108,328 shares of the company's stock valued at $16,547,000 after purchasing an additional 492 shares during the last quarter. Barry Investment Advisors LLC increased its stake in Johnson & Johnson by 2.6% during the 2nd quarter. Barry Investment Advisors LLC now owns 45,874 shares of the company's stock valued at $7,007,000 after purchasing an additional 1,177 shares in the last quarter. Finally, Avior Wealth Management LLC raised its holdings in Johnson & Johnson by 9.0% in the second quarter. Avior Wealth Management LLC now owns 30,409 shares of the company's stock worth $4,645,000 after buying an additional 2,510 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 1.1%

Shares of JNJ opened at $181.63 on Tuesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.87. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company's fifty day simple moving average is $174.76 and its 200-day simple moving average is $162.18. The company has a market cap of $437.43 billion, a P/E ratio of 19.43, a P/E/G ratio of 2.29 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the firm earned $2.82 earnings per share. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Wall Street Zen raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Guggenheim raised Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Royal Bank Of Canada raised their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Tuesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $181.40.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.